FUS mutations

Collaboration Funds Experimental Therapy for Rare FUS-ALS

Eight patients will receive jacifusen, an experimental therapy for amyotrophic lateral sclerosis (ALS) caused by FUS gene mutations, under a joint effort from the ALS Association, Project ALS, and Columbia University’s Eleanor and Lou Gehrig ALS Center. The new clinical research program, which will be supported…

In ALS Study, Essential Protein Seen as Promising New Theurapeutic Target

Researchers have identified an essential protein, Pur-alpha, for motor neuron cells’ mechanisms of defense against external stress and degeneration and also as a potential new therapeutic target for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease). The research paper, “Pur-alpha regulates cytoplasmic stress granule dynamics and ameliorates…